Keywords: زیتاب; Azacitidine; Decitabine; HMAs; Infection; Neutropenia;
مقالات ISI زیتاب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: زیتاب; Epigenetic therapy; Gene reactivation; Immunotherapy; Decitabine; Transplantation;
Keywords: زیتاب; MDS; Allogeneic transplantation; Hypomethylating agents; Azacitidine; Decitabine;
Keywords: زیتاب; Azacitidine; Decitabine; Myelodysplastic syndromes; Response prediction; Combination therapy; Molecular;
Keywords: زیتاب; MDS; myelodysplastic syndromes; AML; acute myeloid leukemia; AZA; azacitidine; DEC; decitabine; LEN; lenalidomide; HI; hematological improvement; SKY; spectral karyotyping; CNV; copy number variation; IWG; International Working Group; HMA; hypomethylating
Keywords: زیتاب; Lymphoma; Methylation; Decitabine; Marginal zone; MALT; CIMP;
Keywords: زیتاب; Azacitidine; Decitabine; High risk and low risk MDS; Myelodysplasia;
Keywords: زیتاب; Blast phase; Decitabine; JAK2; Leukemic transformation; Myeloproliferative neoplasm; Ruxolitinib
Keywords: زیتاب; Allogeneic stem cell transplant; Azacitidine; Decitabine; Investigational agents; IPSS;
Keywords: زیتاب; Drug delivery; Combination therapy; Cancer stem cell; Decitabine; Doxorubicin
Keywords: زیتاب; Acute myeloid leukemia; Azacitidine; Decitabine; Hematopoietic stem cell transplant; Maintenance therapy; Panobinostat; Sorafenib; QuizartinibAML, acute myeloid leukemia; CIBMTR, center for international blood and marrow transplant; CR, complete response;
Keywords: زیتاب; Decitabine; Stem cell transplantation; Maintenance; Myelodysplastic syndrome; Acute leukemia
Keywords: زیتاب; Breast neoplasms; Chemotherapy; Decitabine; Drug resistance; Protein array analysis;
Keywords: زیتاب; MDS; combination; lenalidomide; azacitidine; decitabine; vorinostat; mocetinostat; valproic acid
Keywords: زیتاب; α-KG; alpha-ketoglutarate; 2-HG; 2-hydroxyglutarate; 5hmC; 5-hydroxymethylcytosine; 5mC; 5-methylcytosine; AML; acute myeloid leukemia; ASXL1; additional sex combs-like 1; AZA; azacytidine; CMML; chronic myelomonocytic leukemia; DAC; decitabine; DNMT3A;
Keywords: زیتاب; ALT; alanine aminotransferase; AML; acute myeloid leukemia; AST; aspartate aminotransferase; BUN; blood urea nitrogen; CR; complete response; CRi; complete response with incomplete blood count recovery; ECOG PS; Eastern Cooperative Oncology Group Performa
Keywords: زیتاب; acute myelocytic leukemia; AML; cytokine-induced killer cells; CIK cells; decitabine; elderly; myelodysplastic syndrome; MDS
Keywords: زیتاب; combination therapy; myelofibrosis; ruxolitinib; panobinostat; decitabine; LDE225; PRM-151
Keywords: زیتاب; Azacitidine failure; Azanucleosides; Decitabine; Higher risk; MDS;
Keywords: زیتاب; Treg; Regulatory T cells; Aza; 5-Aza-2â²-deoxycytidine; DNMT; DNA methyltransferase; MLR; Mixed leukocyte reaction; FCM; Flow cytometry; CD4+CD25+ Treg cell; IL-35; Decitabine; Cardiac allograft;
Decitabine induces regulatory T cells, inhibits the production of IFN-gamma and IL-17 and exerts preventive and therapeutic efficacy in rodent experimental autoimmune neuritis
Keywords: زیتاب; Guillain Barrè syndrome; Experimental allergic neuritis; Decitabine; Regulatory T cells;
Intestinal absorption and activation of decitabine amino acid ester prodrugs mediated by peptide transporter PEPT1 and enterocyte enzymes
Keywords: زیتاب; Decitabine; Amino acid ester prodrug; PEPT1; In situ rat perfusion; Oral bioavailability; Molecular docking;
Effects of Decitabine on the proliferation of K562 cells and the expression of DR4 gene
Keywords: زیتاب; DR4 gene; Decitabine; Methylation;
The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia
Keywords: زیتاب; AML; DCAG; Decitabine; Vitamin C; Elderly; TET2;
Do cytogenetics affect the post-remission strategy for older patients with AML in CR1?
Keywords: زیتاب; Acute myeloid leukemia; Age; AML; Azacitidine; Clofarabine; Consolidation; CPX-351; Cytarabine; Cytogenetics; Daunorubicin; Decitabine; Minimal residual disease; MRD; Reduced intensity conditioning; RIC; Risk; TP53; Transplant;
Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells
Keywords: زیتاب; Equilibrative nucleoside transporter 1; Uridine; Decitabine; Deoxycytidine kinase; Monophosphorylation; Irinotecan; Etoposide; Cytarabine; Gemcitabine; Kinetics;
Azacitidine in adult patients with acute myeloid leukemia
Keywords: زیتاب; Azacitidine; Acute myeloid leukemia; AML; Induction chemotherapy; Low-dose cytarabine; Decitabine; CC-486;
Combining Type I Interferons and 5-Aza-2â²-Deoxycitidine to Improve Anti-Tumor Response against Melanoma
Keywords: زیتاب; DAC; decitabine; ISG; interferon-stimulated gene; MDSC; myeloid-derived suppressor cell; MTS; 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; OVA; ovalbumin; PBMC; peripheral blood mononuclear cell; Treg; regulato
Bone-targeting nanoparticle to co-deliver decitabine and arsenic trioxide for effective therapy of myelodysplastic syndrome with low systemic toxicity
Keywords: زیتاب; Myelodysplastic syndrome; Bone marrow; Delivery; Nanoparticle; Decitabine; Arsenic trioxide;
Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients
Keywords: زیتاب; AML; Decitabine; DNA methylation; Elderly; Prognostic
Effects of the combination of decitabine and homoharringtonine in SKM-1 and Kg-1a cells
Keywords: زیتاب; MDS; Decitabine; Homoharringtonine; Apoptosis; Methylation;
Simultaneous quantitative determination of 5-aza-2â²-deoxycytidine genomic incorporation and DNA demethylation by liquid chromatography tandem mass spectrometry as exposure-response measures of nucleoside analog DNA methyltransferase inhibitors
Keywords: زیتاب; 5-Aza-2â²-deoxycytidine; Decitabine; DNA methyltransferase inhibitor; LC/MS/MS; Genomic DNA; Global DNA demethylation; 5-Methyl-2â²-deoxycytidine; 5-Methylcytosine;
Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study
Keywords: زیتاب; MDS; Azacitidine; Decitabine; Comparison;
Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses
Keywords: زیتاب; Decitabine; Hypomethylating agents; Nonmyeloablative conditioning; Hematopoietic cell transplantation; Poor-risk acute myelogenous leukemia/myelodysplastic syndrome;
Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure
Keywords: زیتاب; Azacitidine failure; Decitabine; MDS; CMML
The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome
Keywords: زیتاب; Decitabine; Resistance; hENT1 gene; DCK gene;
Decitabine plus thalidomide yields more sustained survival rates than decitabine monotherapy for risk-tailored elderly patients with myelodysplastic syndrome
Keywords: زیتاب; Decitabine; Thalidomide; Elderly patients; Myelodysplastic syndrome;
Epigenetic regulation of Dnmt3a and Arc gene expression after electroconvulsive stimulation in the rat
Keywords: زیتاب; Electroconvulsive seizures; Activity regulated cytoskeleton-associated protein (Arc); Dnmt3a; DNA methylation; Gene expression; Decitabine;
ReviewComparison Between Decitabine and Azacitidine for the Treatment of Myelodysplastic Syndrome: AÂ Meta-Analysis With 1392 Participants
Keywords: زیتاب; Azacitidine; Decitabine; Hypomethylating agents; Meta-analysis; Myelodysplastic Syndrome;
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase
Keywords: زیتاب; Myeloproliferative neoplasm; AML; Accelerated phase; Myelofibrosis; Decitabine;
Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis
Keywords: زیتاب; Burkitt lymphoma; DNMT1; DNMT3A; DNMT3B; miR-29 family; Decitabine
Decitabine represses osteoclastogenesis through inhibition of RANK and NF-κB
Keywords: زیتاب; DNA methylation; Decitabine; Osteoclast; RANK; NF-κB;
Low-dose decitabine induces MAGE-A expression and inhibits invasion via suppression of NF-κB2 and MMP2 in Eca109 cells
Keywords: زیتاب; Decitabine; MAGE-A; Esophageal squamous cell carcinoma; Invasion; ImmunotherapyESCC, Esophageal squamous cell carcinoma; CTA, Cancer-testis antigens; MAGE-A, Melanoma-associated antigens-A; RT-PCR, Reverse transcription-polymerase chain reaction; RNA, Rib
Development and validation of a HILIC–MS/MS method for quantification of decitabine in human plasma by using lithium adduct detection
Keywords: زیتاب; Lithiated adducts; Alkali adducts; HILIC; Tandem mass spectrometry (MS/MS); Anomerizaton; Decitabine
Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors
Keywords: زیتاب; Decitabine; Demethylating drug; Tumor therapy; Drug sensitivity;
Lipid based nanocarrier system for the potential oral delivery of decitabine: Formulation design, characterization, ex vivo, and in vivo assessment
Keywords: زیتاب; Atomic force microscopy; Decitabine; γ Scintigraphy; Lipid based nanocarrier; Oral drug delivery;
The role of hypomethylating agents in the treatment of elderly patients with AML
Keywords: زیتاب; Acute myeloid leukemia; Azacitidine; Decitabine; Elderly;
Epigenetic action of decitabine (5-aza-2â²-deoxycytidine) is more effective against acute myeloid leukemia than cytotoxic action of cytarabine (ARA-C)
Keywords: زیتاب; 5-Aza-2â²-deoxycytidine; Decitabine; Cytarabine; Acute myeloid leukemia; Chemotherapy; Epigenetics;
Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy
Keywords: زیتاب; Myelodysplastic syndromes; Myelodysplastic-myeloproliferative diseases; Dasatinib; Azacitidine; Decitabine;
Cytogenetic response based on revised IPSS cytogenetic risk stratification and minimal residual disease monitoring by FISH in MDS patients treated with low-dose decitabine
Keywords: زیتاب; Myelodysplastic syndrome; Decitabine; Revised IPSS; FISH; Minimal residual disease;